RDHL Stock Analysis: Buy, Sell, or Hold?
RDHL - Redhill Biopharma Ltd.
$0.83
0.02 (2.47%)
β²
5d:
-18.63%
30d:
-18.63%
90d:
-2.67%
WAIT
LOW Confidence
Analysis Updated: Jun 15, 2026 12:00 AM ET
Earnings: Apr 09, 2026
0d
Get Alerted When RDHL Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
βΈοΈ WAIT FOR STABILIZATION: RDHL is down 18.6% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
βΈοΈ WAIT FOR STABILIZATION: RDHL is down 18.6% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: RDHL is currently trading at $0.83, which is considered oversold relative to its 30-day fair value range of $0.94 to $1.05.
Technical Outlook: Technically, RDHL is in a downtrend. Immediate support is located at $0.80, while resistance sits at $1.09.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $19000.00 (+2289056.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, RDHL is in a downtrend. Immediate support is located at $0.80, while resistance sits at $1.09.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $19000.00 (+2289056.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$0.94 -
$1.05
Company Quality Score
45/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
82.6%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 2289056.6% below Wall St target ($19000.00)
- WARNING: Recommendation downgraded due to -18.6% 5-day decline - wait for stabilization
Trading Range Analysis
30-Day Trading Range
$0.94 -
$1.05
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$0.80
Resistance Level
$1.09
Current Trend
Downtrend
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
1428.57
Wall Street Target
$19000.00
(+2289056.6%)
Revenue Growth (YoY)
58.6%
Profit Margin
-150.0%
Share & Embed Analysis
Last updated: June 16, 2026 12:25 AM ET
Data refreshes hourly during market hours. Next update: 1:25 AM
Data refreshes hourly during market hours. Next update: 1:25 AM
π₯ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is RDHL showing a specific setup today?
Insider Activity (6 Months)
0
Buys
1
Sells
Net
INSIDERS SELLING
Recent Transactions
Gilead Raday
SELL
15740000 shares
2026-04-06
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I⦠|
STRONG BUY
25 analysts |
$193 | 61 BUY |
|
ZTS
Zoetis Inc |
BUY
20 analysts |
$125 | 61 BUY |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$105 | 61 BUY |
|
BCRX
BioCryst Pharmaceuticals⦠|
STRONG BUY
12 analysts |
$21 | 62 BUY |
|
UTHR
United Therapeutics Corp⦠|
STRONG BUY
15 analysts |
$665 | 58 HOLD |